Strategizing Model Selection Across Preclinical Development Stages to Maximize Efficiency & Scientific Impact
- Explaining why complex in vitro models aren't used for screening due to time constraints and model limitations to enable faster decision-making
- Deploying complex three-dimensional models strategically for mechanistic studies to gain deeper biological insights where complexity adds value
- Selecting simpler and faster model systems for other development stages to balance throughput needs with appropriate biological relevance